The Israel-based solar inverter maker, which counts General Electric and Norwest Venture Partners as investors, will go public in the US next week.

The gene editing company, backed by investors including Pfizer, is set to raise almost double its initial target, after pricing a flotation of 5.5 million shares.

The KDDI-backed media curation app developer has filed for an initial public offering that will reportedly value it at about $335m.

Pfizer-backed Cellectis, which is developing cancer treatments, will issue 3.5 million shares and could raise about $129m.

Seachaid Pharmaceuticals-backed Cidara, which is developing therapies to treat fungal infections, has raised $74m in the past two years.

Johnson & Johnson-backed cancer drug developer Aduro has filed for an initial public offering, following a $51.4m series D round in January.

Cosmetic surgery chain Pengai Hospital Management is set to go public in Hong Kong after raising $13.6m from investors including IDG.

Kaiser Permanente-backed Valeritas could raise up to $80m from the initial public offering, and will use the lion's share to market its insulin delivery device.

The Renren-backed alternative lending platform is looking to go public later this year at a $3.5bn valuation, more than double that at which it raised money last month.